BIIB Stock Analysis: Buy, Sell, or Hold?
BIIB - Biogen Inc. Common Stock
$216.12
6.38 (3.04%)
▲
5d:
+7.01%
30d:
+14.45%
90d:
+17.6%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Jul 30, 2026
26d
Smart Money Accumulation
None View Scanner →
Strength: 5.4/10
Get Alerted When BIIB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: BIIB is 7.5% above its trading range ($201.09). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: BIIB is 7.5% above its trading range ($201.09). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$373.99
Based on 14.4% avg growth
INTRINSIC VALUE TODAY
$232.22
6.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BIIB is currently trading at $216.12, which is considered extended relative to its 30-day fair value range of $191.22 to $201.09. From a valuation perspective, the stock is trading at a premium (Forward PE: 13.0) compared to its historical average (11.6). At these levels, the market is pricing in 3.8% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, BIIB is in a uptrend. The price is approaching resistance at $219.72. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.0% recently.
Market Sentiment: BIIB has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, BIIB is in a uptrend. The price is approaching resistance at $219.72. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.0% recently.
Market Sentiment: BIIB has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$191.22 -
$201.09
Company Quality Score
67/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
58.1%
Protect Your Profits
Holding BIIB? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range (+7.5% above its trading range)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.0%)
- NEUTRAL: Near Wall St target ($220.28)
- NEUTRAL: Market pricing in 3.8% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$191.22 -
$201.09
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$193.20
Resistance Level
$219.72
Current Trend
Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
13.00
Wall Street Target
$220.28
(+1.9%)
Revenue Growth (YoY)
1.9%
Earnings Growth (YoY)
31.1%
Profit Margin
13.8%
Valuation Premium vs History
+3.8% premium
PE vs Historical
13.0 vs 11.6
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.8%
(market-implied from PE analysis)
1-Year Target
$224.33
(+4%)
2-Year Target
$232.86
(+8%)
3-Year Target
$241.71
(+12%)
3-Yr Target (if PE normalizes)
(PE: 13→12)
PE COMPRESSION
$215.69
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 24.8%)
$703.34
(+225%)
Base:
(SPY PE: 13.0, Growth: 24.8%)
$419.79
(+94%)
Bear:
(PE: 11.0, Growth: 24.8%)
$356.82
(+65%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (23x PE), but valuation improves significantly next year (13x PE) as earnings recover.
Trailing PE: 22.58 | Current EPS (TTM): $9.29
Bull Case
$412.89
(+91%)
Analyst growth 79.0%, PE expands to 24.8
Base Case
$375.35
(+74%)
Market implied 79.0%, PE stable at 22.6
Bear Case
$142.62
(-34%)
Severe decline -20.0%, PE contracts to 19.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 03, 2026 4:07 PM ET
Data refreshes hourly during market hours. Next update: 5:07 PM
Data refreshes hourly during market hours. Next update: 5:07 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BIIB showing a specific setup today?
Insider Activity (6 Months)
3
Buys
3
Sells
0
Net
INSIDERS SELLING
Recent Transactions
Nicole Murphy
BUY
3 shares
2026-02-12
Priya Singhal
SELL
2660 shares
2026-02-09
Ro Khanna
SELL
2026-02-06
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1223 | 61 BUY |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 67 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$353 | 69 BUY |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$254 | 60 HOLD |
|
MRK
Merck & Company Inc |
BUY
26 analysts |
$130 | 62 BUY |
Advanced BIIB Option Strategies
Professional options setups generated by AI based on today's BIIB price and gamma walls.
